Biodesix, Inc.
NASDAQ:BDSX
0.7221 (USD) • At close March 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 71.323 | 49.087 | 38.212 | 54.506 | 45.557 | 24.552 | 20.432 |
| Cost of Revenue
| 0 | 13.01 | 14.154 | 30.518 | 21.998 | 6.074 | 4.406 |
| Gross Profit
| 71.323 | 36.077 | 24.058 | 23.988 | 23.559 | 18.478 | 16.026 |
| Gross Profit Ratio
| 1 | 0.735 | 0.63 | 0.44 | 0.517 | 0.753 | 0.784 |
| Reseach & Development Expenses
| 9.559 | 9.988 | 13.102 | 12.789 | 10.818 | 10.468 | 8.188 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 30.637 | 25.899 |
| Selling & Marketing Expenses
| 0 | 0 | 61.462 | 50.517 | 34.857 | 30.637 | 25.899 |
| SG&A
| 80.451 | 67.387 | 61.462 | 50.517 | 34.857 | 30.637 | 25.899 |
| Other Expenses
| 15.811 | 0.044 | 0.109 | -0.009 | 0.422 | -2.379 | -1.235 |
| Operating Expenses
| 105.821 | 77.419 | 74.564 | 63.306 | 45.675 | 41.105 | 34.087 |
| Operating Income
| -34.498 | -41.342 | -50.506 | -39.318 | -22.116 | -22.627 | -23.461 |
| Operating Income Ratio
| -0.484 | -0.842 | -1.322 | -0.721 | -0.485 | -0.922 | -1.148 |
| Total Other Income Expenses Net
| -8.433 | -10.804 | -14.86 | -2.219 | -8.416 | -3.985 | -2.705 |
| Income Before Tax
| -42.931 | -52.146 | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Income Before Tax Ratio
| -0.602 | -1.062 | -1.713 | -0.792 | -0.688 | -1.251 | -1.281 |
| Income Tax Expense
| 0 | 0 | 14.941 | 1.321 | 5.123 | 0.629 | 0.211 |
| Net Income
| -42.931 | -52.146 | -80.388 | -44.48 | -36.473 | -31.355 | -26.166 |
| Net Income Ratio
| -0.602 | -1.062 | -2.104 | -0.816 | -0.801 | -1.277 | -1.281 |
| EPS
| -0.33 | -0.64 | -1.91 | -1.63 | -1.37 | -1.23 | -0.99 |
| EPS Diluted
| -0.33 | -0.64 | -1.91 | -1.63 | -1.37 | -1.23 | -0.99 |
| EBITDA
| -34.498 | -37.103 | -53.778 | -35.473 | -20.843 | -24.925 | -21.51 |
| EBITDA Ratio
| -0.484 | -0.756 | -1.319 | -0.722 | -0.476 | -0.902 | -0.858 |